Mesothelioma Brain Metastasis: 2.7% Prevalence and the First Genetic Profiling (Stanford 2026)

Key Facts About Mesothelioma Brain Metastasis in 2026

• Pooled CNS prevalence: 2.7% (18 of 655 mesothelioma patients in seven autopsy series; Miller 2014)
• Histologic distribution in CNS-metastatic mesothelioma: sarcomatoid 31, biphasic 14, epithelioid 14 (of 59 specified cases)
• Histologic dedifferentiation between primary and brain sites: 17% of paired cases — meaning a brain biopsy may not look like the original tumor
• Pooled peritoneal mesothelioma cases with CNS metastasis: zero in 655 autopsies and 97 reviewed clinical cases — a striking organ-specific pattern
• First-ever genetic profiling: Stanford team led by Paul M. Harary, published Cancer Reports, May 2026 (PMID 42101078)
• Stanford Case 1: 20-to-25-year-old male with pericardial mesothelioma; 14 bilateral brain lesions; RAD51C missense variant of uncertain significance; 21.25-month overall survival
• Stanford Case 2: 85-to-90-year-old male with pleural mesothelioma; hemorrhagic frontotemporal lesion; NF2 splice-site and TP53 frameshift mutations; 6-month post-brain-metastasis survival on stereotactic radiosurgery
• Standard first-line systemic therapy for pleural mesothelioma: nivolumab plus ipilimumab, median overall survival 18.1 months (CheckMate-743)
• Standard hippocampal-avoidance WBRT outcome: 0.74 adjusted hazard ratio for cognitive failure versus standard WBRT (NRG Oncology CC001)

What Is Mesothelioma Brain Metastasis and Why Is It Rare?

Mesothelioma is a cancer of the mesothelial cells that line the chest cavity (pleural mesothelioma), abdomen (peritoneal mesothelioma), heart sac (pericardial mesothelioma), or testicular tunic. The disease typically progresses locally and through regional lymph nodes. Distant spread to the brain via the bloodstream is uncommon — but it does happen.

The most rigorous estimate comes from a 2014 pooled analysis by Miller and colleagues at the National Cancer Institute and the NIH Clinical Center. Their systematic review of seven autopsy studies — Adams 1986, Finn 2012, Hartman 1996, Hulks 1989, Huncharek 1987, Schlienger 1969, and Whitwell 1971 — combined 655 mesothelioma patients with complete central nervous system pathologic evaluation at autopsy. Eighteen patients (2.7%) had CNS metastases identified, with individual study rates ranging from 0% to 3.8%.

The clinical incidence on brain imaging is likely lower because most mesothelioma patients die of advanced thoracic or peritoneal disease before brain spread becomes evident, and routine brain imaging is not standard mesothelioma staging or surveillance. Miller and colleagues wrote: "Clinicians should consider and identify CNS involvement in patients with new or evolving neurologic symptoms because early identification may allow for palliative intervention." That guidance matters in practice — new or progressive headaches, seizures, focal weakness, speech changes, or mental-status changes in a mesothelioma patient warrant contrast-enhanced brain MRI rather than reassurance.

One particularly striking finding from the Miller pooled analysis: zero cases of primary peritoneal mesothelioma metastasizing to the central nervous system were identified across the autopsy series of 655 patients or the 97 reviewed clinical cases. The organ-specific pattern is real and distinguishes peritoneal mesothelioma from pleural disease in this respect.

What Did the Stanford 2026 Study Find?

In May 2026, Harary, Hori, Jain, Kattaa, Gephart, Gensheimer, Soltys, Park, and Chang from Stanford University School of Medicine published the first dedicated genetic and immunohistochemical profiling of mesothelioma with brain metastasis in Cancer Reports (Hoboken). The study covered two cases reviewed under Stanford Institutional Review Board protocol #3910. Hybrid-capture next-generation sequencing was performed on formalin-fixed paraffin-embedded tumor tissue.

Case 1 — Pericardial Mesothelioma, RAD51C Variant

A 20-to-25-year-old male presented with left arm shaking, and brain MRI revealed 14 total brain lesions, 85.7% with vasogenic edema. Subsequent workup confirmed a pericardial primary tumor with epithelioid histology. The patient had no documented asbestos exposure. Family history was notable: a maternal aunt with breast cancer at 33 and acute myeloid leukemia at 35. Next-generation sequencing identified a RAD51C missense mutation (c.492 T>G, p.F164L), classified as a variant of uncertain significance. No paired germline testing was performed despite the young age, asbestos-naive status, and family history that would have justified it.

Treatment included whole-brain radiotherapy at 30 Gy in 10 fractions (six fractions with hippocampal avoidance), postoperative nivolumab plus ipilimumab, and later gemcitabine 1000 mg/m². Overall survival was 21.25 months from initial mesothelioma diagnosis.

Case 2 — Pleural Mesothelioma, NF2 + TP53 Mutations

An 85-to-90-year-old male presented with expressive aphasia. Brain imaging revealed a large hemorrhagic frontotemporal lesion. The primary tumor was pleural mesothelioma, again without documented asbestos exposure. Sequencing identified two simultaneous somatic alterations: an NF2 splice-site mutation (c.1731_1737del+7, variant allele fraction 23%) and a TP53 frameshift mutation (c.295_296del, variant allele fraction 27%). The authors characterize the TP53 frameshift as "unusual for MM" — only 14% of pleural mesotheliomas carry TP53 point mutations or subgenic deletions with probable biallelic inactivation, per the Chapel 2022 reference cohort of 84 tumors.

Treatment was stereotactic radiosurgery: 22 Gy in a single dose for the frontotemporal lesion and 20 Gy in a single fraction for a subsequent right parietal lesion, with 16% volume reduction at three months on follow-up imaging. Systemic therapy was carboplatin AUC 3.5 plus pemetrexed 400 mg/m² for three cycles — doses reduced from the adult standard reflecting geriatric oncology dose-reduction practice. Post-brain-metastasis survival was six months, characterized by the authors as relatively favorable for this setting.

"Two cases is not a randomized trial, but for the families I have walked through this diagnosis, a published genetic profile of mesothelioma at the brain metastasis site is something that did not exist before May 2026. The conversations I have sat in on between patients and their oncology teams have shifted because of papers like this — families I have supported are now asking about whether next-generation sequencing of a brain biopsy is available, where a year ago that question did not come up, particularly when the patient is young, has no documented asbestos exposure, or has a family cancer history."

— David Foster, Director of Client Services, Danziger & De Llano

Why Do the NF2, TP53, and RAD51C Findings Matter?

The four tumor-suppressor genes most directly implicated in mesothelioma — BAP1, CDKN2A/MTAP, NF2, and TP53 — have been characterized in detail by Chapel and colleagues at Brigham and Women's Hospital in a 2022 study of 84 pleural mesotheliomas. Pathogenic alterations occur at the following frequencies: BAP1 in 56%, CDKN2A in 69%, NF2 in 68%, and TP53 in 27% of cases. The Stanford 2026 study reports an NF2 splice-site mutation in Case 2 that fits the established NF2 loss-of-function spectrum, and a TP53 frameshift that falls within the smaller (14%) subset of TP53 mutations with probable biallelic inactivation.

The RAD51C variant in Case 1 is more novel. RAD51C is a homologous-recombination repair gene; germline RAD51C mutations are an established moderate-penetrance risk factor for breast and ovarian cancer. Whether RAD51C variants predispose to mesothelioma is not yet established in the published literature. A relevant precedent comes from Schaefer et al. (2023, Modern Pathology), who documented a pathogenic BRCA1 germline mutation with somatic biallelic inactivation in one of three primary pericardial mesotheliomas — establishing that homologous-recombination germline mutations can drive this rare cancer subtype. The Stanford case adds RAD51C to the list of homologous-recombination genes worth examining in pericardial mesothelioma, though germline status remains unresolved without paired blood sequencing.

For diagnostic workup, the Chapel 2022 study validated a BAP1 + MTAP + Merlin three-marker immunohistochemistry panel at 90% sensitivity and 100% specificity for pleural mesothelioma versus reactive mesothelial proliferations. Adding p53 immunohistochemistry brings the four-marker panel to 93% sensitivity. Combined with hybrid-capture next-generation sequencing, the diagnostic yield reaches 99%. For a brain biopsy where the original tumor's histology may have undergone dedifferentiation (17% of paired cases per Miller 2014), running the full panel is what protects against misdiagnosis.

How Is Mesothelioma Brain Metastasis Treated?

Radiation therapy is the workhorse of local management for mesothelioma brain metastasis, with the choice between whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) driven by lesion number, lesion size, performance status, and overall systemic disease control.

For limited brain metastases — typically up to 10–15 lesions — SRS is generally preferred. The maximum tolerated single-fraction doses established by RTOG 90-05 (Shaw et al., 2000) are 24 Gy for tumors ≤20 mm, 18 Gy for 21–30 mm, and 15 Gy for 31–40 mm. The Stanford Case 2 doses of 22 Gy and 20 Gy for ~15 mm lesions fall within standard practice.

For numerous lesions or when SRS is not feasible, hippocampal-avoidance WBRT (HA-WBRT) plus memantine is now the cognitive-preservation standard following the NRG Oncology CC001 Phase III trial (Brown et al., 2020). In 518 patients with brain metastases, HA-WBRT plus memantine reduced the risk of cognitive function failure compared with standard WBRT plus memantine — adjusted hazard ratio 0.74, with significantly less deterioration in executive function and memory measures. Stanford Case 1 used 30 Gy in 10 fractions with six fractions hippocampal-avoidance, consistent with this evidence.

The Stanford authors explicitly recommend stereotactic radiosurgery over whole-brain radiotherapy for mesothelioma brain metastasis in most circumstances, citing shorter treatment time and easier combination with systemic therapy. For lesions larger than 3 cm, fractionated SRS is generally preferred to reduce radiation necrosis risk.

Systemic therapy is determined by the primary disease, not by the brain metastasis. For unresectable pleural mesothelioma, the standard since October 2020 has been nivolumab plus ipilimumab per CheckMate-743 (Baas et al., Lancet 2021) — median overall survival 18.1 months versus 14.1 months with platinum-pemetrexed chemotherapy. Case 1's postoperative use of nivolumab plus ipilimumab for pericardial mesothelioma is off-label, reflecting the absence of regulatory-approved regimens for that rare primary site.

"The clients and families I have supported through a brain-involvement diagnosis have told me the same thing again and again: the centers where they felt their care was the most coordinated were the ones where medical oncology, radiation oncology, neurosurgery, and neuropathology actually met together about their case. The Stanford report describes a multidisciplinary configuration — stereotactic radiosurgery for the limited lesion, hippocampal-avoidance whole-brain radiotherapy when the lesion count was high — and that kind of team alignment is what our clients have most often described as the most helpful when they have navigated brain metastasis."

— David Foster, Director of Client Services, Danziger & De Llano

Who Should Ask About Genetic Testing or Brain Imaging?

The Stanford study's most actionable implication is for two specific patient profiles. First, any mesothelioma patient with new or progressive neurological symptoms should have contrast-enhanced brain MRI promptly. Routine brain surveillance is not standard, so symptoms are the trigger. Second, young, asbestos-naive, or family-history-positive mesothelioma patients — particularly those with pericardial or peritoneal primary disease — should have germline cancer-predisposition testing considered. The Stanford Case 1 patient checked all three boxes and germline testing was not performed; the authors flag this gap explicitly in their discussion of unanswered research questions.

Available germline panels typically include BAP1, BRCA1, BRCA2, and the broader homologous-recombination genes (RAD51C, RAD51D, PALB2, ATM, CHEK2). For a mesothelioma diagnosis, your oncology team can refer you to a genetic counselor; some academic mesothelioma centers offer germline testing through research protocols at no cost to the patient.

For broader medical context, see WikiMesothelioma's Mesothelioma Brain Metastasis reference page (the encyclopedic companion to this article) and the Pleural Mesothelioma page. For clinical-trial searches, the ClinicalTrials.gov database can be filtered for mesothelioma plus eligibility language permitting treated or stable brain metastases.

Compensation Pathways When Brain Metastasis Is Part of the Diagnosis

A mesothelioma diagnosis remains compensable under U.S. asbestos law regardless of whether the disease has spread to the brain. Asbestos manufacturers that filed for bankruptcy protection under Section 524(g) of the U.S. Bankruptcy Code maintain asbestos trust funds — currently holding approximately $30 billion in aggregate — to compensate exposure victims regardless of disease stage. Trust fund claims are not contingent on the location of metastasis; the underlying mesothelioma diagnosis carries the claim.

The Stanford 2026 cases highlight an additional consideration. Both patients had no documented asbestos exposure, which complicates traditional occupational-exposure attribution. In young-onset, asbestos-naive, or family-history-positive mesothelioma, germline cancer-predisposition testing may be relevant both to clinical management and to legal strategy — establishing the etiologic differential is part of how strong claims are built. For a free, no-obligation evaluation of compensation pathways, including in unusual or asbestos-naive presentations, visit Danziger & De Llano's mesothelioma resource center or call (855) 699-5441. Additional patient resources are available through Mesothelioma.net.

References

1. Harary PM, Hori YS, Jain R, Kattaa AH, Gephart MH, Gensheimer MF, Soltys SG, Park DJ, Chang SD. Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases. Cancer Rep (Hoboken). 2026 May;9(5):e70571. PubMed ID 42101078.
2. Miller AC, Miettinen M, Schrump DS, Hassan R. Malignant mesothelioma and central nervous system metastases: report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc. 2014 Sep;11(7):1075-81. PubMed ID 25079105.
3. Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod Pathol. 2022 Oct;35(10):1383-1397. PubMed ID 35459788.
4. Schaefer IM, Mariño-Enríquez A, Hammer MM, Padera RF, Sholl LM. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma. Mod Pathol. 2023 Sep;36(9):100237. PubMed ID 37295554.
5. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743). Lancet. 2021 Jan 30;397(10272):375-386. PubMed ID 33485464.
6. Brown PD, Gondi V, Pugh S, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine, NRG Oncology CC001. J Clin Oncol. 2020 Apr 1;38(10):1019-1029. (Brain-metastasis methodology trial — any-primary-tumor cohort.)
7. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8. (Brain-metastasis methodology trial — any-primary-tumor cohort.)
8. WikiMesothelioma. Mesothelioma Brain Metastasis (encyclopedic reference, 2026).
9. WikiMesothelioma. Pleural Mesothelioma (encyclopedic reference).
10. Danziger & De Llano. Mesothelioma Treatment Options Overview.
11. Mesothelioma.net. Mesothelioma Patient Support and Diagnosis Resources.